NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)

Long term, multi-year supply agreement provides Alpha-9 with NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in Alpha-9’s targeted radiopharmaceutical programs for treatment of solid and liquid tumors. Agreement will support Alpha-9’s ongoing development and clinical programs in addition to multiple undisclosed discovery-stage programs. NorthStar is positioned to be one of the first […] The post NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225) appeared first on Alpha-9 Oncology .